KRAS inhibitors market size
Jan 08, 2024
Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C
The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like sotorasib and adagrasib directly target KRAS G12C by forming a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
